Annual Report

The report describes GSK's strong 2013 turnover and R&D performance, including six significant new product approvals. It highlights a 33% female Board, a global workforce of 99,451 employees, and a 60% increase in medicines supplied to Least Developed Countries since 2010. The company also reports Scope 1 and 2 emissions, a 2050 carbon-neutral value-chain target and environmental initiatives covering water and waste. Its responsible-business discussion further emphasizes clinical-trial transparency, access to healthcare and the malaria-vaccine program.